STAT+: Lawsuit against Hims & Hers should be ‘wake-up call’ for compounders, Novo chief counsel says

Novo Nordisk has initiated legal action against Hims & Hers, a telehealth company, for allegedly infringing on a key patent related to its weight-loss drug, Wegovy. The lawsuit arises from Hims & Hers offering a compounded version of Wegovy at a lower price, which Novo Nordisk has criticized as an “untested knockoff.” The chief counsel of Novo has stated that telehealth companies and compounding pharmacies producing copycat versions of Wegovy should be “very, very much on notice” regarding the legal implications of their actions. In response to the legal challenges and an ongoing investigation by the FDA, Hims & Hers has decided to cease the sale of its compounded weight-loss pill. The company had been marketing this alternative for €41, which drew significant criticism from Novo Nordisk, the Danish pharmaceutical company that developed Wegovy. Novo Nordisk's accusations against Hims & Hers include claims of “illegal mass compounding,” highlighting the company's concerns over the safety and efficacy of the unregulated compounded product. The situation has raised broader concerns within the pharmaceutical and telehealth industries regarding the legality and ethical implications of producing compounded medications that mimic established drugs. Novo Nordisk's actions signal a strong stance against what it perceives as infringement on its intellectual property and a potential risk to patient safety. The outcome of this lawsuit could have significant repercussions for both companies and the compounding pharmacy sector as a whole.